Antioxidant micronutrients and childhood malignancy during oncological treatment

Malvy, Denis; Arnaud, Josiane; Burtschy, Bernard; Sommelet, D.; Leverger, Guy; Dostálová, L.; Amédée-Manesme, O

doi:10.1002/(sici)1096-911x(199709)29:3<213::aid-mpo9>3.0.co;2-g

Cited by 32 publications

(25 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were also confirmed by Zuo et al and Unal et al, who found decreased zinc levels in serum of leukemic patients (Zuo et al, 2006) and in serum of Hodgkin's disease patients, respectively (Unal et al, 2001). Moreover, decreased blood levels of antioxidants (i.e., retinol, α-tocopherol, and β-carotene) and zinc were found in childhood malignancies (Malvy et al, 1993(Malvy et al, , 1997, which could be one of the negative effects of zinc-metabolism alterations. Zinc deficiency has also been associated with oxidative stress (OS) (Eide, 2011) and esophageal, head and neck cancer, and prostate and other cancer types, especially in their development and progression (Franklin and Costello, 2007;Hogstrand et al, 2009;Ostrakhovitch, 2011;Fukada et al, 2011;Pedersen et al, 2009).…”

Section: S Krizkova Et Alsupporting

confidence: 75%

Metallothioneins and zinc in cancer diagnosis and therapy

Křížková¹,

Ryvolová²,

Hraběta³

et al. 2012

Drug Metabolism Reviews

View full text Add to dashboard Cite

Metallothioneins (MTs) are involved in protection against oxidative stress (OS) and toxic metals and they participate in zinc metabolism and its homeostasis. Disturbing of zinc homeostasis can lead to formation of reactive oxygen species, which can result in OS causing alterations in immunity, aging, and civilization diseases, but also in cancer development. It is not surprising that altered zinc metabolism and expression of MTs are of great interest in the case of studying of oncogenesis and cancer prognosis. The role of MTs and zinc in cancer development is tightly connected, and the structure and function of MTs are strongly dependent on Zn²⁺ redox state and its binding to proteins. Antiapoptic effects of MTs and their interactions with proteins nuclear factor kappa B, protein kinase C, esophageal cancer-related gene, and p53 as well as the role of MTs in their proliferation, immunomodulation, enzyme activation, and interaction with nitric oxide are reviewed. Utilization of MTs in cancer diagnosis and therapy is summarized and their importance for chemoresistance is also mentioned.

show abstract

Section: S Krizkova Et Alsupporting

confidence: 75%

Metallothioneins and zinc in cancer diagnosis and therapy

Křížková¹,

Ryvolová²,

Hraběta³

et al. 2012

Drug Metabolism Reviews

View full text Add to dashboard Cite

show abstract

“…[20] In a few studies, although the transferrin level has been reported to be an indicator that accompanies malnutrition, it has been stated that it was not as sensitive as prealbumin. [21] In the present study, 59 (96.7%) of the patients had dysphagia. Fifty-three patients (86.9%) had a history of weight loss while 43 (70.5%) patients had a cachectic appearance.…”

Section: Discussionsupporting

confidence: 47%

Prognostic importance of serum CRP, prealbumin, and transferrin levels in patients with advanced stage esophageal cancer

Aydın¹

2011

Turkish J Thorac Cardiovasc Surg

View full text Add to dashboard Cite

Amaç: Bu çalışmada stent takılarak tedavi edilen ileri evre özofagus kanserli hastalarda serum C-reaktif protein (CRP), prealbumin ve transferrin düzeylerinin prognostik değeri araştırıldı. Ça lış ma pla nı: Temmuz 2007 ve Aralık 2008 tarihleri arasında gerçekleştirilen prospektif randomize bir çalış-mada lokal olarak ilerlemiş hastalık veya uzak organ metastazı nedeniyle stent takılarak tedavi edilen ardışık 61 hastada, stent takılmadan 1-3 gün önce serum CRP, prealbumin ve transferrin düzeyleri çalışıldı. Tüm hastalar ölünceye kadar takip edildi. Bul gu lar: Stent tüm hastalarda başarı ile takılarak oral alım tekrar sağlandı. İşleme bağlı mortalite gözlenmedi. Hastaların ortalama sağkalım süresi 164.3±120.3 gün (dağılım 15-450 gün) idi. Serum CRP seviyesi ≥10 mg/L olan hastalarda (n=38) ortalama sağkalım 103.2±82.3 gün iken serum CRP seviyesi <10 mg/L olan hastalarda (n=23) ortalama sağkalım 265.4±121.2 gün idi. Serum prealbumin seviyesi ≥15 mg/L olan hastalarda (n=28) ortalama sağkalım 237.5±132.7 gün iken serum prealbumin seviyesi <15 mg/L olan hastalarda (n=33) ortalama sağkalım 102.3±79.6 gün idi. Serum transferrin seviyesi ≥200 mg/L olan hastalarda (n=25) ortalama sağkalım 211.6±130.2 gün iken serum transferrin seviyesi <200 mg/L olan hastalarda (n=36) ortalama sağkalım 131.5±113.8 gün idi. Referans serum CRP, prealbumin ve transferrin seviyelerinin sağ-kalımla ilişkisi istatistiksel olarak anlamlı idi (sırasıyla p<0.001, p<0.001 ve p= 0.003). So nuç: İleri evre özofagus kanserli hastalarda özofageal stent uygulamasından önce serum CRP, prealbumin ve transferrin düzeyleri kolaylıkla saptanabilir ve hastaların prognozları hakkında fikir elde edilebilir.Anah tar söz cük ler: C-reaktif protein; özofagus kanseri; prealbü-min; sağkalım; transferrin.Background: This study investigated the prognostic value of serum C-reactive protein (CRP), prealbumin, and transferrin levels in patients with advanced stage esophageal cancers treated with stent placement. Methods: In a prospective, randomized study conducted between July 2007 and December 2008, serum CRP, prealbumin, and transferrin levels were determined 1-3 days prior to stent placement in 61 consecutive patients who underwent stent placement due to locally advanced disease or distant organ metastasis. All patients were followed until death. Results:The stent was successfully placed in all patients and oral intake was restored. There was no procedure-related mortality. The mean survival period of the patients was 164.3±120.3 days (range 15 to 450 days). Whereas the mean survival period was 103.2±82.3 days in patients with a serum CRP level ≥10 mg/L (n=38), it was 265.4±121.2 days in patients with a serum CRP level <10 mg/L (n=23). While the mean survival period was 237.5±132.7 days in patients with a serum prealbumin level ≥15 mg/L (n=28), the mean survival period was 102.3±79.6 days in patients with a serum prealbumin level <15 mg/L (n=33). The mean survival period was 211.6±130.2 days in patients with a serum transferrin level ≥200 mg/L (n=25) while the mean ...

show abstract

“…Moreover, a study that analyzes the oxidative profile in children just diagnosed with ALL in comparison to that of the different stages of treatment has not been found in the literature. Other studies evaluated antioxidant status in children with newly diagnosed ALL and during the first months of chemotherapy [31,32], but not with patients out-of-treatment. In this context, we have examined the activities of antioxidant enzymes (SOD, CAT) as well as thiol, vitamin E and MDA levels and protein carbonylation in the blood of just diagnosed ALL patients as compared to those in the different stages of treatment and after therapy.…”

Section: Discussionmentioning

confidence: 99%